Sat, Feb 28, 2015, 10:09 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • tjnelis tjnelis Dec 20, 2012 12:28 PM Flag

    incyte recently awarded tax refund/abatemen/relief

    says some really interesting things from management
    1. company not up for sale anytime soon, as there is a clawback on the tax relief until 2018
    2. management believes it must have a big pipeline ahead. why else would it want to double
    its present overhead by 2018,,,,,roughly going from 80m a q to breakeven to 160m
    3. are jakafi sales breaking out? instead to flattening out?
    4 could there be a bigger buyback clause with lly after p3?

    hurdles ahead in the road or not
    1 fiscal cliff
    2 obama care
    3 no new drugs, or new uses of a drug on the market in 2013, possibly 2014
    4 is there enough money , to accomplish this, or will there be shareholder dilution?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I've been saying for years, literally, that sale of the company looks remote. I've also been saying since Summer that something big other than a buyout has to be in the works to justify the ongoing embarrassment of the "dark" pipeline.

      Obamacare is mostly a plus for a company with a costly life-saving drug. I've been told that there IS a problem for small drug developers: it explicitly lets insurance companies off the hook on paying for off-label uses of drugs. Too many important cancer drugs are used off-label for that to be allowed to turn into flat denial of coverage, but it'll make life harder.

      I used to talk constantly about the stretched-'S' shape of the typical drug adoption curve. We've been living on the low-slope leading toe of that curve for Jakafi. At some moment we get to the middle steep part; I'll guess by Summer. If the safety profile still looks as good then as it has so far, there should be a lot of pressure to put the 10% of PV patients and maybe 5% of ET patients who are sickest onto it too, which will let the steep part run longer than it would otherwise.

      Whatever the hush-hush dealing is about, and however delicate it may be, it pretty much has to end by the time marketing for bari' becomes the major focus--say a year and a half (I get the image of a woman pregnant for 3 years). I really can't imagine that much suffering being assumed for anything that doesn't generate enough money to do independent drug development (say, $a couple hundred MM). All this secrecy doesn't say pure financial maneuvering (high dilution). Wouldn't be too surprising to see the deal sweetened with SOME dilution, though.

    • Forgot to add.....we are talking 10 million dollars...not enough for anyone to hesitate buying them! Please keep it real.....if possible?

      Sentiment: Strong Buy

    • TJ,

      It is all about state of Delaware giving them incentive to remain in Delaware. Both PA and NJ want them to relocate. They are outgrowing their present space. I agree that big things are on horizon as they are doubling headcount.

85.85-1.69(-1.93%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.